BHRT and TRT via telehealth: what Oklahoma patients should know
Quick answer
The video promotes a telehealth-based hormone therapy service in Oklahoma offering testosterone, compounded creams, and oral hormones for both men and women, with lab work bundled into the initial visit. Testosterone is correctly identified as a Schedule III controlled substance, which legally restricts prescribing and shipment to within Oklahoma state lines. Clinicians evaluating patients remotely for TRT should follow Endocrine Society guidelines requiring documented hypogonadism and baseline cardiovascular risk screening before initiating therapy.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @np2go actually say?
Alexa from NPDGo told viewers that yes, hormone replacement therapy, including testosterone, can be handled entirely via telehealth in Oklahoma. Labs get drawn locally, the consultation happens by phone or video, and medications ship to your door. The one exception she named: pellet placement requires an in-person visit. She quoted pricing of $399 for the first month (labs, consult, meds bundled) and $199 monthly after that.
She also flagged something important: "testosterone is a scheduled substance" and can only be prescribed and shipped within Oklahoma state lines. This is not a minor disclaimer. It is the legal backbone of everything she described, and she handled it more honestly than most telehealth hormone ads do.
Does the science back this up?
The telehealth delivery model for TRT is legitimate and increasingly well-studied. A 2022 analysis in The Journal of Urology (Chu et al.) found that telehealth testosterone prescribing increased substantially post-COVID without evidence of worsened clinical outcomes. Remote lab ordering, symptom assessment, and follow-up are all supported in clinical guidelines from the American Urological Association and the Endocrine Society.
The modalities she mentioned, including injections, creams, and oral medications, are all FDA-recognized delivery routes for testosterone in men and women. Oral testosterone undecanoate (Jatenzo, Tlando) received FDA approval for men. Compounded transdermal creams are widely used off-label for women with low androgen levels, though evidence for symptom benefit in women remains more mixed than in men. The Endocrine Society's 2023 guidelines are cautious about routine testosterone use in women outside of carefully documented hypoactive sexual desire disorder.
What did they get wrong (or right)?
Credit where it is due: she correctly identified testosterone as a Schedule III controlled substance under the DEA, which means interstate prescribing and shipping require in-state licensure. Most TRT telehealth ads skip this entirely. She did not.
What she glossed over is the clinical nuance around "getting your hormones balanced." That phrase does real work in hormone marketing, and it deserves scrutiny. There is no universally agreed-upon definition of "balanced" hormones. Reference ranges vary by lab, age, and sex. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) showed testosterone therapy in middle-aged men with hypogonadism did not increase major cardiac events but did raise rates of atrial fibrillation and pulmonary embolism. That is not a reason to avoid TRT, but it is a reason a telehealth consult should include a real cardiovascular risk assessment, not just a lab draw and symptom checklist.
She also listed "oral medications" as a hormone option without specifying which. For women, oral estrogen carries higher VTE risk than transdermal routes. For men, most oral testosterone formulations require fat with meals for absorption. These are not trivial details to leave out of a public-facing video.
What should you actually know?
If you are in Oklahoma and considering hormone therapy via telehealth, the model NPDGo describes is legally plausible and clinically workable, but the $399 entry price is only meaningful if the consultation is thorough enough to catch contraindications. That means asking about cardiovascular history, clotting risk, sleep apnea, and prostate health for men, not just symptoms of fatigue or low libido.
Telehealth TRT platforms vary enormously in prescribing standards. A 2021 study in JAMA Internal Medicine (Jasuja et al.) found that testosterone prescribing without documented hypogonadism diagnosis is common and problematic. Ask your provider which diagnostic criteria they use before any prescription is written.
- BHRT pellets, which she mentioned as the one in-office requirement, carry specific risks including infection, pellet extrusion, and difficulty titrating doses once implanted. The North American Menopause Society notes pellets are not FDA-approved for hormone therapy.
- "Feeling better" after starting hormones may reflect placebo response, lifestyle changes, or actual hormonal correction. Baseline and follow-up labs matter for distinguishing these.
Is a $399 telehealth hormone visit a good deal?
Compared to cash-pay endocrinology or gynecology visits, the bundled pricing is competitive. Hormone panels at direct-to-consumer lab services like LabCorp or Quest can run $150 to $300 alone. The math is not unreasonable if the clinical quality is there.
The risk with membership-based hormone clinics is that the business model favors retention, not necessarily reassessment. If your labs normalize and your symptoms resolve, will the platform recommend stopping or reducing therapy? That question is worth asking before you sign up for month two at $199.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For BHRT and TRT via telehealth: what Oklahoma patients should know, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Core review for NAD+ decline, mitochondrial function, DNA repair, and aging biology.
PubMed
Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
Human NMN source for metabolic claims while keeping population limits clear.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
BHRT and TRT via telehealth: what Oklahoma patients should know is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes a telehealth-based hormone therapy service in Oklahoma offering testosterone, compounded creams, and oral hormones for both men and women, with lab work bundled into the initial visit.
FormBlends verdict
The video promotes a telehealth-based hormone therapy service in Oklahoma offering testosterone, compounded creams, and oral hormones for both men and women, with lab work bundled into the initial visit. Testosterone is correctly identified as a Schedule III controlled substance, which legally restricts prescribing and shipment to within Oklahoma state lines. Clinicians evaluating patients remotely for TRT should follow Endocrine Society guidelines requiring documented hypogonadism and baseline cardiovascular risk screening before initiating therapy.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes a telehealth-based hormone therapy service in Oklahoma offering testosterone, compounded creams, and oral hormones for both men and women, with lab work bundled into the initial visit. Testosterone is correctly identified as a Schedule III controlled substance, which legally restricts prescribing and shipment to within Oklahoma state lines. Clinicians evaluating patients remotely for TRT should follow Endocrine Society guidelines requiring documented hypogonadism and baseline cardiovascular risk screening before initiating therapy.
- Testosterone is a Schedule III controlled substance under federal law, making in-state licensure mandatory for telehealth prescribing and shipping. NPDGo correctly disclosed this limitation.
- The TRAVERSE trial (Lincoff et al., 2023, NEJM) found TRT did not increase major cardiac events but did raise rates of atrial fibrillation and pulmonary embolism, risks a telehealth intake must screen for.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Testosterone is a Schedule III controlled substance under federal law, making in-state licensure mandatory for telehealth prescribing and shipping. NPDGo correctly disclosed this limitation.
- The TRAVERSE trial (Lincoff et al., 2023, NEJM) found TRT did not increase major cardiac events but did raise rates of atrial fibrillation and pulmonary embolism, risks a telehealth intake must screen for.
- A 2021 JAMA Internal Medicine study (Jasuja et al.) found testosterone prescribed without documented hypogonadism is a widespread problem in telehealth settings. Ask your provider which diagnostic criteria they use.
- Hormone pellets, the one service requiring an in-person visit per this video, are not FDA-approved for hormone therapy and carry unique risks including difficult dose adjustment once implanted.
- The Endocrine Society's 2023 guidelines express caution about routine testosterone use in women outside of documented hypoactive sexual desire disorder, meaning the evidence base for female TRT is weaker than for male hypogonadism.
- Bundled telehealth pricing around $399 is cost-competitive with cash-pay hormone panels and specialist visits, but membership models may create financial incentives to continue therapy even when clinical reassessment would suggest tapering.
- Oral and transdermal hormone routes are not clinically interchangeable. Route of administration affects VTE risk, bioavailability, and dosing schedules in ways that should be individualized, not listed as equivalent options in a general video.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Np2Go · TikTok creator
11.3K views on this video
Replying to @turtlesunday Yes. We do offer telehealth visits for hormones in Oklahoma only (for now). Our price is $399 for initial visit/labs/medications and $199/monthly starting after a month afterthe initial visit. #np2go #bhrt #menopause #perimenopause #trt
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Np2Go, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.